%0 Journal Article
%T Low Incidence along with Low mRNA Levels of EGFRvIII in Prostate and Colorectal Cancers Compared to Glioblastoma
%A Cezary Treda
%A Ewelina Stoczynska-Fidelus
%A Joanna Peciak
%A Kamila Rosiak
%A Karolina Janik
%A Krystyna Hulas-Bigoszewska
%A Maciej Smolarz
%A Magdalena Ksiazkiewicz
%A Marta Popeda
%A Piotr Rieske
%A Waldemar Och
%A Wojciech J Stec
%J Journal of Cancer
%D 2017
%I Ivyspring International Publisher
%R 10.7150/jca.16108
%X Background: The presence as well as the potential role of EGFRvIII in tumors other than glioblastoma still remains a controversial subject with many contradictory data published. Previous analyses, however, did not consider the level of EGFRvIII mRNA expression in different tumor types. Methods: Appropriately designed protocol for Real-time quantitative reverse-transcription PCR (Real-time qRT-PCR) was applied to analyze EGFRvIII and EGFRWT mRNA expression in 155 tumor specimens. Additionally, Western Blot (WB) analysis was performed for selected samples. Stable cell lines showing EGFRvIII expression (CAS-1 and DK-MG) were analyzed by means of WB, immunocytochemistry (ICC) and fluorescence in situ hybridization (FISH). Results: Our analyses revealed EGFRvIII expression in 27.59% of glioblastomas (8/29), 8.11% of colorectal cancers (3/37), 6.52% of prostate cancers (3/46) and none of breast cancers (0/43). Despite the average relative expression of EGFRvIII varying greatly among tumors of different tissues (approximately 800-fold) or even within the same tissue group (up to 8000-fold for GB), even the marginal expression of EGFRvIII mRNA can be detrimental to cancer progression, as determined by the analysis of stable cell lines endogenously expressing the oncogene.
%K EGFRvIII
%K prostate cancer
%K colorectal cancer
%K breast cancer
%K glioblastoma
%K Real-time quantitative reverse-transcription PCR.
%U http://www.jcancer.org/v08p0146.htm